Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Miles D. and Ciruelos E. and Schneeweiss A. and Puglisi F. and Peretz-Yablonski T. and Campone M. and Bondarenko I. and Nowecki Z. and Errihani H. and Paluch-Shimon S. and Wardley A. and Merot J.-L. and Trask P. and du Toit Y. and Pena-Murillo C. and Revelant V. and Klingbiel D. and Bachelot T. and Bouzid K. and Desmoulins I. and Coudert B. and Glogowska I. and Ciruelos Gil E. and Dalenc F. and Ricci F. and Dieras V. and Kaufman B. and Ferreira A. and Mano M. and Kalofonos H. and Hitre Erika and Láng István and Horváth Zsolt and Bodoky György and Kahán Zsuzsanna and Kollaborációs szervezet: PERUSE investigators and et al.: Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
ANNALS OF ONCOLOGY, 32 (10). pp. 1245-1255. ISSN 0923-7534 (2021)

Actions (login required)